The active ingredient in Ozempic was associated with a reduced risk of Alzheimer's disease-related dementia among diabetes patients.

The exact numbers depended on the type of medication patients took, but the risk of developing Alzheimer’s was up to 70 ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type 2 diabetes.

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the secret to staving off Alzheimer’s, too.

Obesity and diabetes drugs, particularly semaglutides like Wegovy and Ozempic, may reduce a person’s risk of dementia, a new study suggests.

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk and potential applications for addiction treatment.

“According to the latest figures released by the NHS, dementia diagnosis is at a record high in England. “This is great news for residents, as increased awareness results in increased ...

Ozempic and similar novel diabetes treatments may lower the risk of Alzheimer's disease and related dementias. This is the conclusion of a pair of studies by research teams from the U.S. and ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.